drugset / Trial / NCT06221774
Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors
Phase 1/2
Unknown
42 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This Phase Ib/II clinical study is an open-label, multi-cohort, two-stage trial designed to assess the safety and efficacy of different doses of TT-00420 tablets in combination with Toripalimab injection for treating patients with advanced urological tumors. The study aims to evaluate the effectiveness of TT-00420 tablets at the optimal dose combined with Toripalimab in treating different types of advanced urological tumors.
Timeline
- Start
- 2024-02-01
- Primary completion
- 2025-08-31
- Completion
- 2025-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tinengotinib | Small molecule | 8 mg | — |
| Subject | Tinengotinib | Small molecule | 10 mg | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |